Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

@article{Seyedmousavi2015PharmacodynamicsOI,
  title={Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.},
  author={Seyedmojtaba Seyedmousavi and Roger J M Br{\"u}ggemann and Jacques F Meis and Willem J G Melchers and Paul E Verweij and Johan W Mouton},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 5},
  pages={2855-66}
}
Azole resistance is an emerging problem in Aspergillus fumigatus which translates into treatment failure. Alternative treatments with new azoles may improve therapeutic outcome in invasive aspergillosis (IA) even for strains with decreased susceptibility to current azoles. The in vivo efficacy of 0.25, 1, 4, 16, 64, 128, 256, and 512 mg/kg of body weight/day prodrug isavuconazonium sulfate (BAL8557) (isavuconazole [ISA]-equivalent doses of 0.12, 0.48, 1.92, 7.68, 30.7, 61.4, 122.9, and 245.8 mg… CONTINUE READING
16 Citations
66 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 66 references

Similar Papers

Loading similar papers…